240125 PR_BIOCORP
Posts By: Sylvaine Dessard
BIOCORP reports half-year results as of June 30, 2023
230904 PR_BIOCORP_H1 results
Completion of Novo Nordisk’s acquisition of a controlling stake in BIOCORP
230804 PR_BIOCORP
Signing of the definitive agreements in connection with the acquisition by NOVO NORDISK of a controlling stake in BIOCORP
230619 PR BIOCORP
Novo Nordisk enters into exclusive negotiations to acquire a controlling stake in BIOCORP, to be followed by a tender offer on all remaining shares.
230605 PR BIOCORP
BIOCORP: Full-Year 2022 financial results and outlook for 2023
230329 PR BIOCORP
2023 – Financial calendar – New
230320 PR_BIOCORP
BIOCORP signs with HRA Pharma for the development of a medical device innovation
230314 PR BIOCORP
2023 financial calendar
230105 PR_BIOCORP
BIOCORP completes a €2.5 million convertible bond issue subscribed by funds managed by Vatel Capital
230102 PR BIOCORP